Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami
read moreHow Anemocyte is Changing History as a Biotech Manufacturing Organization (BMO)
read moreAt the cutting edge of Cell and Gene therapy and a centre of excellence for the production of plasmids and non-viral solutions for genetic modifications, Anemocyte will be a key player at the leading sector event thanks to its expertise, dynamism and industrial cell and plasmid manufacturing facilities
read moreThe Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer
read moreA new state-of-the-art facility dedicated to plasmid manufacturing will be in operation by August 2019 in Gerenzano, Italy. The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space. With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors
read moreCell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene therapy products from manufacturing sites to clinical centers
read moreThe discussion moves onto goes onto the fine line between success and failure, examining the stories of Apollo 13, Thomas Edison and Elizabeth Gilbert, the author of Eat. Pray. Love. Dwayne explores failure and its negative connotations. Failure provides an opportunity to learn and to display passion to others, it’s an iteration on the road to success. In the immortal words of the great Thomas Edison
read moreWith a swell of R&D activity flowing into the development of cell and gene therapies over the past decade, a manufacturing shortage gripped the industry. This caused industry participants to express grave fears that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these new types of living therapies
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
